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1. Introduction  
The drug problem in the United States is a complex mosaic involving different types of 
drugs, consumption practices, and biological and psychological responses to their effects. 
Over the past two decades, the fields of psychiatry and neurology have witnessed dramatic 
scientific breakthroughs in understanding the actions of drugs that can be used to regulate 
the nervous system (Nestler, Hyman, & Malenka, 2009). This has led to a dramatic increase 
in use of these medications for treating a wide range of physical and mental disorders 
(Dasgupta et al., 2006). An unintended consequence of this increased level of availability is 
that a large proportion of these drugs are being consumed in excess of the dosage 
recommended by the manufacturer or prescriber, used to self-treat illnesses instead of 
seeking professional medical care, and/or combined with other drugs increase the desired 
effects. As a result, the numbers of unintentional poisonings and emergency room visits 
have nearly doubled. For instance, the latest figures from the Drug Abuse Warning Network 
(DAWN) indicate that in 2008, that nearly half of the 2 million emergency room visits to U.S. 
hospitals involved prescription medications. Approximately two-thirds of those visits that 
involved prescription medications were for prescription pharmaceuticals only and no co-
occurring illicit drug or alcohol abuse (SAMHSA, 2006). In addition to the tremendous 
economic costs associated with overdoses involving prescription medications, the adverse 
social and mental/physical health effects, though difficult to directly quantify, are 
considerable. 
The goal of this chapter is to present an overview of the current state of knowledge about 
the nonmedical use of prescription medications. Because of the sheer volume of the 
literature, this chapter cannot cover the entire breadth of this complex phenomenon. 
Therefore, the discussion is limited to those exhibiting features of dependence on 
prescription medications, as this is the most harmful pattern of use. Within the context of 
dependence, the goal is to present a concise review of the epidemiological data on the 
prevalence of dependence on prescription medications within various population sub-
groups (e.g. youth, those with co-occurring illicit substance use disorders, and previous 
history of psychiatric illness). In addition, a brief summary is provided on the 
pharmacological properties that are likely to confer selective use of the particular drug 
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class for nonmedical use. Information on the prevalence of seeking treatment for a 
substance use disorder involving prescription drugs, unmet need for treatment, and types 
of evidence-based treatment available for each drug class is also presented. Surveillance 
data also indicate that nonmedical use occurs in a wide range of medication classes (e.g., 
anabolic steroids, over-the-counter cough medicines, antihistamines) (Compton & 
Volkow, 2006; Kuehn, 2007; Lankenau, Sanders, Bloom, & Hathazi, 2008). However, this 
chapter focuses on the three classes of medications where the epidemiological and 
physiological literatures indicate that the likelihood of transitioning beyond 
experimentation to dependence is greatest—pain relievers, stimulants, and 
sedatives/tranquilizers (Blanco et al., 2007). Unless otherwise noted, the source of the 
surveillance data is the 2005-2009 National Survey on Drug Use and Health (NSDUH). It 
is a cross-sectional survey of non-institutionalized youth (age 12-17) and adults (age 18+) 
in the United States that is conducted on an annual basis and arguably contains the richest 
source of data covering topics related to the nonmedical use of prescription medications 
(Colliver, Kroutil, Dai, & Gfroerer, 2006).  
2. Taxonomy of nonmedical prescription drug use 
The term nonmedical use of prescription drugs has been criticized in the literature because 
studies typically define it use as a single item. However, NMPD is a multidimensional 
construct that encompasses a wide range of motivations to use prescription medications 
(Boyd & McCabe, 2008). Unlike heroin or other illicit drugs, prescription medications can 
be used to treat legitimate medical conditions. With the exception of cocaine, most illicit 
drugs are defined by the Drug Enforcement Agency in the United States as having no 
medical therapeutic value and therefore are considered illegal to possess or dispense 
(Table 1).  
An important side note deserves mentioning. Marijuana and cocaine have some level of 
medically accepted therapeutic value and are available in certain States only under 
extremely unique circumstances. For instance, marijuana is currently treated by the US 
federal government as having no medically accepted therapeutic value and is therefore 
considered illegal (See Table 2). A small number of States (e.g., California, Colorado) 
consider marijuana an acceptable treatment, such as for patients with glaucoma. In those 
states, it is available from a licensed prescriber and may be obtained from a specialized 
pharmacy licensed to dispense limited quantities to patients. Cocaine is used as a topical 
anesthetic for conditions of the eye and nose, including nasal cauterization. However, 
prescriptions for cocaine and marijuana are highly regulated.  
 
Substances: 
Categories and 
Names 
Examples of 
Commercial and 
Street Names 
DEA Schedule* / 
How 
Administered** 
Intoxication Effects / 
Potential Health 
Consequences 
Depressants 
  barbiturates Amytal, Nembutal, 
Seconal, Phenobarbital; 
barbs, reds, red birds, 
phennies, tooies, 
yellows, yellow jackets 
II, III, V/injected, 
swallowed 
Reduced pain and anxiety; 
feeling of well-being; lowered 
inhibitions; slowed pulse and 
breathing; lowered blood 
pressure; poor 
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Substances: 
Categories and 
Names 
Examples of 
Commercial and 
Street Names 
DEA Schedule* / 
How 
Administered** 
Intoxication Effects / 
Potential Health 
Consequences 
  benzodiazepines 
(other  
  than flunitrazepam) 
Ativan, Halcion, Librium, 
Valium, Xanax; candy, 
downers, sleeping pills, 
tranks 
IV/swallowed concentration/confusion, 
fatigue; impaired coordination, 
memory, judgment; respiratory 
depression and arrest, 
addiction 
For barbiturates – sedation, 
drowsiness/depression, 
unusual excitement, fever, 
irritability, poor judgment, 
slurred speech, dizziness 
For benzodiazepines – sedation, 
drowsiness/dizziness 
For flunitrazepam – visual and 
gastrointestinal disturbances, 
urinary retention, memory loss 
for the time under the drug’s 
effects 
  flunitrazepam***+ Rohypnol; forget-me pill, 
Mexican Valium, R2, 
Roche, roofies, roofinol, 
rope, rophies 
IV/swallowed, 
snorted 
Opioids and Morphine Derivatives 
  codeine   Empirin with Codeine, 
Fiorinal with Codeine, 
Robitussin A-C,  
Tylenol with Codeine; 
Captain Cody,  
Cody, schoolboy; 
(with glutethimide doors 
& hours,  
loads, pancakes 
and syrup 
II, III, IV/injected, 
swallowed 
Pain relief, euphoria, 
drowsiness/respiratory 
depression and arrest, nausea, 
confusion, constipation, 
sedation, unconsciousness, 
coma, tolerance, addiction 
For codeine – less analgesia, 
sedation, and respiratory 
depression than morphine 
  fentanyl Actiq, Duragesic, 
Sublimaze;  
Apache, China girl, 
China white,  
dance fever, friend, 
goodfella,  
jackpot, murder 8,  
TNT,  
Tango and Cash 
II/injected, smoked, 
snorted 
  morphine Roxanol, Duramorph; M, 
Miss Emma, monkey, 
white stuff 
II/injected, 
swallowed, smoked 
  opium laudanum, paregoric;  
big O, black stuff,  
block, gum, hop 
II, III, V/swallowed, 
smoked 
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Substances: 
Categories and 
Names 
Examples of 
Commercial and 
Street Names 
DEA Schedule* / 
How 
Administered** 
Intoxication Effects / 
Potential Health 
Consequences 
  other opioid pain 
relievers   
  (oxycodone, 
meperidine,  
  hydromorphone,  
  hydrocodone,   
  propoxypene) 
Tylox, OxyContin, 
Percodan, Percocet; oxy 
90s, oxycotton, oxycet, 
hillbilly heroin, percs 
Demerol, meperidine 
hydrochloride; demmies, 
pain killer 
Dilaudid; juice, dillies 
Vicodin, Lortab, Lorcet, 
Darvon, Darvocet 
II, III, IV/swallowed, 
injected, 
suppositories, 
chewed, crushed, 
snorted 
Stimulants 
  amphetamines Biphetamine, Dexedrine; 
bennies, black beauties, 
crosses, hearts, LA 
turnaround, speed, truck 
drivers, uppers 
II/injected, 
swallowed, smoked, 
snorted 
Increased heart rate, blood 
pressure, metabolism; feelings 
of exhilaration, energy, 
increased mental 
alertness/rapid or irregular 
heart beat; reduced appetite, 
weight loss, heart failure 
For amphetamines – rapid 
breathing; 
hallucinations/tremor, loss of 
coordination; irritability, 
anxiousness, restlessness, 
delirium, panic, paranoia, 
impulsive behavior, 
aggressiveness, tolerance, 
addiction 
For cocaine – aggression, 
violence, psychotic 
behavior/memory loss, cardiac 
and neurological damage; 
impaired memory and 
learning, tolerance, addiction 
For methylphenidate – increase 
or decrease in blood pressure, 
psychotic episodes/ digestive 
problems, loss of appetite, 
weight loss 
  cocaine Cocaine hydrochloride; 
blow, bump, c, candy, 
Charlie, coke, crack, 
flake, rock, snow, toot 
II/injected, smoked, 
snorted 
  methamphetamine Desoxyn; chalk, crank, 
crystal, fire, glass, go 
fast, ice, meth, speed 
II/injected, 
swallowed, smoked, 
snorted 
  methylphenidate Ritalin; JIF, MPH, R-ball, 
Skippy, the smart drug, 
vitamin R 
II/injected, 
swallowed, snorted 
*Schedule I and II drugs have high potential for abuse. They require greater storage security and have a quota on 
manufacturing, among other restrictions. Schedule I drugs are available for research only and have no approved 
medical use; Schedule II drugs are available only by prescription (unrefillable) and require a form for ordering. 
Schedule III and IV drugs are available by prescription, may have five refills in 6 months, and may be ordered 
orally. Most Schedule V drugs are available over the counter. 
**Taking drugs by injections can increase the risk of infection through needle contamination with staphylococci, 
HIV, hepatitis, and other organisms. 
***Associated with sexual assaults. 
+Not available by prescription in the U.S. 
Table 1. Selected Prescription Drugs with Potential for Abuse 
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Substance 
Category 
Definition Example Drugs 
Schedule I  Most restrictive level 
 Includes drugs or other substances 
with a high potential for abuse 
 No currently accepted medical use 
in the United States 
 Low level of safety 
 Not approved for use, distribution, 
manufacture, or importation 
Heroin 
Marijuana 
Phencyclidine (PCP) 
Lysergic acid dithylamide 
(LSD) 
Schedule II  Drugs have high abuse potential 
 Have currently accepted medical 
use in treatment, with severe 
restrictions 
Cocaine 
Methamphetamine 
Amphetamines 
Dextroamphetamine 
Adderall® 
Morphine 
Oxycodone 
OxyContin® 
Methylphenidate 
Ritalin® 
Schedule III  Drugs have abuse potential less 
than that of Schedule I or II drugs 
 Have currently accepted medical 
uses in treatment 
Hydrocodone 
Vicodin® 
Butalbital 
Fiorinal® 
Schedule IV  Drugs have lower abuse potential 
than those of Schedule III drugs 
 Have currently accepted medical 
uses in treatment 
Alprazolam 
Xanax® 
Diazepam 
Valium® 
Propoxyphene 
Darvon® 
Schedule V  Drugs have low abuse potential 
 Have recognized medical uses 
 Some pharmaceuticals contain 
drugs with higher abuse potential 
but in much lower concentrations 
relative to other ingredients 
 
Cough medicines with codeine 
Robitussin AC® 
Table 2. Drug Enforcement Agency’s Controlled Substances Act Definitions of Substances 
Subject to Food and Drug Administration Regulation 
Notwithstanding marijuana and cocaine, many illicit drugs were originally developed for 
medicinal purposes, but were deemed to have little or no efficacy, or having such a high 
abuse liability that they were prohibited as a legal medical treatment (e.g., heroin, LSD). 
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Therefore, prescription medications are unique in that their use is motivated by factors other 
than euphoria. For instance, prescription pain relievers are often used to treat legitimate 
medical injuries, but many patients self-treat without a doctor’s prescription when a dosage 
of the drug is readily available to them (e.g., using a spouses prescription).  
Attempts to develop survey items to capture the concept of nonmedical use has been 
challenging because there is no universally accepted definition as to what constitutes 
nonmedical use prescription drug use (NMPD). The National Survey on Drug Use and 
Health (NSDUH) frames the question as whether the respondent “used a particular drug 
that was not prescribed for you or was used only for the experience or feeling it caused.”   It 
is sometimes argued that the NSDUH definition of NMPD is overly inclusive, as it could 
include drugs that are used for self-treatment of a medical condition, but were not 
specifically prescribed by a physician (Huang et al., 2006). In contrast, another annual cross-
sectional surveillance study focused on youth, the Monitoring the Future (MTF) study 
defines nonmedical prescription drug use as ‘use of prescription medications without a 
doctor telling you to take them’ (Johnston, O’Malley, Bachman, & Schulenberg, 2009). Then, 
the survey follows with queries about motivations about the most important reason for use, 
such as: experimentation, pain relief, euphoria. Understanding motivations for use are 
important because nonmedical users who use only for therapeutic value and those using for 
other reasons, such as for euphoria, are likely to have different profiles of risk and protective 
factors for use, abuse liabilities, and prevention and treatment needs (Zachny and Lichtor, 
1998; Boyd and McCabe).  
In the United States, there is a tremendous gulf among legislative stakeholders in terms of a 
formal taxonomy for nonmedical prescription drug use and problematic levels of use. The 
Food and Drug Administration has urged manufactured to focus on “Physical Dependence” 
and “Tolerance” (Dasgupta, Henningfield, Ertischek, & Schnoll, 2011) in the assessment of 
abuse liability for prescription medications. The National Institutes of Health (NIH) is 
concerned both the physical and psychological aspects of addiction that are linked to extant 
diagnostic criteria, such as the American Psychiatric Association’s Diagnostic and Statistical 
Manual (DSM) or the International Classification of Diseases (ICD) categories of abuse and 
dependence (Compton & Volkow, 2006). The United States Drug Enforcement Agency 
(DEA) takes a more scientific approach, focusing on the legal requirements (e.g., number 
and timing of refills, quantity dispensed under a single prescription, written versus 
ePrescribing) that is tied to a drug’s particular abuse liability (Katz et al., 2007). The words 
“abuse” and “misuse” have often been used interchangeably, but may be used to define 
separate acts of nonmedical use. The term Abuse may refer to use that involves seeking a 
euphoric “high” and misuse typically refers to “intentional use that involves a legitimate 
prescription that is used in amounts not directed by the prescriber or to treat another 
medical condition.” An additional piece of this complicated taxonomy is whether the drug 
was prescribed for the user or whether they obtained it illicitly (e.g., stole/obtained from 
friends/family, forged written prescription, feigned symptoms to a prescriber with liberal 
prescribing habits [pill mills] (Boyd & McCabe, 2008).  
In 2003, the College on Problems on Drug Dependence, the largest professional society in 
the United States dedicated solely to the advancement of knowledge about drug abuse, 
published a position statement about prescription pain relievers (Zacny et al., 2003). The 
statement urged for a formal clarification of the term nonmedical use that is broad enough 
to include motivations for use for inclusion on national surveillance surveys, such as the 
NSDUH. However, the purpose of this chapter focuses on the epidemiology and treatment 
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of levels of use that are problematic and in need of specialty substance abuse treatment. 
Therefore, clarification of the term nonmedical use is less important than resolution of the 
diagnostic criteria that can be used to assess problem use, such as the DSM or ICD 
classifications of abuse or dependence. There is some debate about the degree to which 
opioids differ in their abuse liability and phenotypic expression of abuse and/or 
dependence symptoms (Wu, Woody, Yang, & Blazer, 2011; Wu, Woody, Yang, Mannelli, & 
Blazer, 2011). However, DSM and ICD criteria are generally accepted measures that can be 
easily translated onto epidemiological surveys to estimate the population in need of 
substance abuse treatment services for prescription drug-related problems. There are many 
clinical tools that are used to diagnose problem use for different therapeutic classes, as well 
as biological challenge tests of physical dependence (Kosten, Bianchi, & Kosten, 1989). At 
one end of the continuum, there is concern that the “one-size fits all” approach to defining 
the concepts of abuse and dependence may not operate similarly across all substances even 
within a therapeutic class (e.g., extended release having lower abuse liability than 
immediate release oxycodone) (Dasgupta, et al., 2011). At the other end of the continuum, 
there is an argument that abuse and dependence are a continuum, which is derived from an 
underlying biopsychosocial propensity (Krueger et al., 2002). Regardless of the placement 
on the spectrum, the term Addiction refers to a chronic and relapsing pattern of use and is 
defined by essentially three characteristics: compulsive use, loss of control in limiting intake, 
and altering behavioral activities in support of drug consumption. Medical professionals 
typically employ more specific terminology aligned within clinical (e.g., DSM or ICD 
criteria) criteria when referencing disordered patterns of substance use, such as abuse 
and/or dependence.  
For the remainder of this chapter, we present data on problem levels of prescription drug 
use using the DSM-IV/ICD classification scheme of abuse and/or dependence. This 
scheme is the most widely employed diagnostic tool for problem use on national 
surveillance data systems, and are used to frame the nation’s perspective and 
conversation related to research, prevention, treatment, and public policy toward the 
nonmedical use of prescription drugs. Within this diagnostic taxonomy, hierarchical 
criteria are used to ensure that substance use disorders are classified by whether 
symptoms are directly tied to substance use or a separate psychiatric disorder or illness. 
For example, mood and anxiety disorders (APA, 2006) have exclusionary criteria because 
a common symptom of withdrawal (e.g., “dope sick”) may involve symptomotology that 
overlaps with mood and anxiety disorders, such as “feeling downhearted and blue” or 
“nervousness”. This task is complicated by the high rate of comorbidity between mental 
(i.e., mood, anxiety, and personality) and substance use disorders (McLellan, Lewis, 
O'Brien, & Kleber, 2000; NIDA, 1999; O'Brien et al., 2004).  
Evaluating a substance use disorder has been established using criteria that can be 
implemented by a clinician, or a trained interviewer using a semi-structured instrument, 
such as the Structured Clinical Interview for DSM Axis II disorders (First, 2002). There are 
also many diagnostic tools that are fully structured and can be implemented in the context 
of a research interview. These include the Composite International Diagnostic Interview 
[CIDI] (Green et al., 2011; Haro et al., 2006; Kessler et al., 2004)and the Associated 
Disabilities Interview Schedule [AUDADIS] (Grant et al., 2003; Grant, Harford, Dawson, 
Chou, & Pickering, 1995). Ascertaining the count of the population in need of services is a 
challenge because of the resources needed to execute a full diagnostic exam on a 
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sufficiently large enough sample that permits generalization to the population as a whole. 
However, such a task is critical for policymakers to help identify and prioritize placement 
of finite resources that are funded through public monies. As mentioned earlier, there are 
a small number of surveys that collect data annually on nonmedical  use of prescription 
drugs, but only one implements a fully-structured diagnostic interview for substance use 
disorders annually for youth (age 12-17) and adults (ages 18 or older—the National 
Survey on Drug Use and Health (SAMHSA, 2008). Other annual surveys administer brief 
screening scales that can be used to assess probable case based on a small number of 
items. A drawback is that they lack the sensitivity and specificity to accurately assess the 
number in need of treatment (Aldworth et al., 2010; Novak, Colpe, Barker, & Gfroerer, 
2010). Therefore, in-depth diagnostic scales provide the best approach to capturing the 
complex phenomena of substance abuse disorders, despite the length and expense in their 
implementation.  
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) distinguishes 
problematic substance use along two categorical rubrics (shown in Table 3):  
 ABUSE: Captures a maladaptive pattern of use that causes significant impairment in 
social, mental, and physical life-world domains. An example is missing work or failing 
to attend to household obligations because of use. Continued use despite consistent 
interpersonal or social problems associated with use is another hallmark system.  
 DEPENDENCE: Is defined by a maladaptive pattern of use with adverse clinical 
consequences. Dependence involves two physical aspects: (1) Tolerance—refers to the 
decrease in the physical or psychological effects of a constant dosage of a drug over 
time; and (2) Withdrawal—refers to a physiological state of adverse mental and physical 
symptoms (e.g., nausea, insomnia, muscle aches/pains, These symptoms will vary 
depending upon how long the medication was taken and the type of medication.  
In the next section, we summarize the epidemiology of nonmedical prescription drug use, 
with an emphasis on disordered patterns of use as defined by DSM-IV criteria (APA, 2002). 
Surveillance data are drawn from the National Survey on Drug Use and Health (SAMHSA, 
2009). The NSDUH is an annual, nationally representative survey of youth (age 12-17) and 
adults (age 18 or older) in the United States. The procedures and characteristics of the 
sample have been published extensively elsewhere (SAMHSA, 2008). Briefly, the sample 
includes approximately 65,000 respondents each year. The target population is the civilian, 
noninstitutionalized population of the United States (including civilians living on military 
bases) and residents of noninstitutional group quarters (e.g., college dormitories, group 
homes, civilians dwelling on military installations) and persons with no permanent 
residence (homeless people in shelters and residents of single rooms in hotels). The NSDUH 
collects information on a large range of illicit substances, including consumption patterns, 
treatment utilization, and diagnoses aligned with the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) criteria for abuse and/or dependence (APA, 2000) for alcohol 
and selected drugs. For this paper, Substance use treatment was coded if the respondent 
reported any therapy or treatment, including detoxification and treatment for any medical 
problems associated with their drug use. Unmet treatment need was defined as the presence 
of a past-year DSM-IV diagnosis for abuse and/or dependence on prescription medications, 
but the respondent did not report receiving substance abuse treatment. Due to the complex 
sampling design of the NSDUH, all descriptive and inferential analyses were conducted 
with SUDAAN release 10.0 (RTI, 2009).  
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Disorders Definition 
Substance Use Disorders 
  Substance Dependence 
A maladaptive pattern of substance use with adverse 
clinical consequences. The DSM-IV has widened the concept 
of dependence to include the association of substance use 
with uncontrolled use or with use in spite of adverse 
consequences. 
  Substance Abuse 
A maladaptive pattern of substance use that causes clinically 
significant impairment, not meeting dependence criteria. 
This may include impairments in social, family, or 
occupational functioning, in the presence of a psychological 
or physical problem, or in satiations in which use of the 
substance is physically hazardous, such as driving while 
intoxicated. 
Substance Induced Disorders 
  Substance Intoxication 
Reversible, substance-specific physiological and behavioral 
changes due to recent exposure to a psychoactive substance. 
Produced by all substances. 
  Substance Withdrawal 
A substance-specific syndrome that develops following 
cessation of or reduction in dosage of a regularly used 
substance. Occurs with chronic use of all substances, except 
perhaps cannabis and hallucinogens. 
  Substance Induced Delirium 
  (confusion, psychosis) 
Occurs with overdose of many substances 
  Substance Induced Psychotic Disorder
  (psychosis) 
May occur with phenylcyclidine (PCP) and hallucinogens, 
stimulants, cannabis, and alcohol. 
  Substance Induced Mood Disorder 
  (depression, mania) 
  Anxiety 
Common with many substances, especially alcohol and 
stimulants. Disorder must be distinguished from primary 
psychiatric disorder that preceded drug use. 
  Substance Induced Sleep Disorder 
A sleep disturbance attributable to acute or chronic 
substance use. Common with alcohol, sedatives, and 
stimulants. 
  Substance Induced Sexual Dysfunction
Alcohol, benzodiazepines, and opioids commonly reduce 
sexual responsiveness and performance. 
  Substance Induced Persisting 
Disorders 
Substance-specific syndromes that persist long after drug 
use ceases (e.g., hallucinogen “flashbacks,” memory 
impairments, or dementia). 
* dsm-iv criteria (american psychiatric association, 1994) 
Table 3. Classification of Substance Use and Substance Induced Disorders* 
3. Patterns of prescription drug use and disordered use in the United States 
Although trend data indicate that the prevalence of nonmedical use of prescription drugs 
has nearly doubled over the past two decades (Blanco, et al., 2007), the rate of nonmedical 
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use remained fairly consistent over the past 5 years (Figure 1). Among youth (aged 12-17), 
the NSDUH showed that approximately 8 percent (8,000 per 100,000) used any class of 
prescription medication in the prior year. Among those that used, about 16% met the criteria 
for abuse or dependence (Figure 2). The rate of use far exceeds that of adults (aged 18 or 
older) where approximately 6% used any prescription medication non-medically and the 
 
 
Fig. 1. Past Year Nonmedical Prescription Drug Use and Meeting Criteria for Dependence or 
Abuse of Nonmedical Prescription Drugs, by Age and Year: 2005-2009 NSDUH (per 100,000) 
 
 
Fig. 2. Past Year Substance Use Disorder among Persons Receiving Drug Treatment in the 
Past Year, by Age and Year: 2005-2009 NSDUHs (In Percent) 
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rates of disordered use was about 16%, similar to adolescents. These data suggest that 
problematic levels of abuse are developing far earlier in lifecourse, especially compared to 
other drugs, such as heroin and cocaine where the median age of disordered use is in the 
mid 20s (SAMSHA, 2006). Additional data (Figure 2) indicate that adolescent females are 
progressing to abuse/dependence more rapidly than males. Among those that received any 
form of treatment for a substance use disorder in the United States (about 2.3 million in 
2009), Figure 3 reveals that approximately 15% to 18% met the criteria for a prescription 
drug disorder. A concern about drug treatment is that care usually focuses on eliminating 
the most harmful substance in the client’s drug-taking repertoire, so prescription drug 
disorders often go unrecognized and untreated compared to illicit drugs such as cocaine 
and heroin. When broken down by the amount of co-occurring disorders among those in 
treatment, Figure 4, shows that of those in drug treatment that have a prescription drug 
disorder, about 70% have a co-occurring drug and/or alcohol use disorder as well.  
 
 
Fig. 3. Past Year Substance Use Disorders Among Persons Aged 18 or Older Receiving Past 
Year Drug Treatment, by Year: 2005-2009 NSDUHs 
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Fig. 4. Poly Drug Use Disorder among Persons with NMPD Use Disorder, by Age and Year: 
2005-2009 NSDUHs 
 
 
 
Fig. 5. Percent of Past Year Nonmedical Prescription Drug Use and Meeting Criteria for 
Dependence or Abuse of Nonmedical Prescription Drugs among 12-17 years olds, by Sex 
and year: 2005-2009 NSDUHs 
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4. Prescription pain relievers  
Therapeutic Indications: Pain relievers as a therapeutic medication class are also referred to as 
analgesics. They are distinguished by the ways in which they act in the peripheral or central 
nervous system. Analgesics that are non-steroidal anti-inflammatory drugs (NSAIDS) are 
used to treat mild pain and act by reducing inflammation at the site of an injury or disease 
in the body. NSAIDS typically do not require a prescription in the United States and are 
available “over-the-counter” (OTC) at local pharmacies, drug stores, and even gas stations. 
Other types of (OTC) analgesics are not NSAIDS (e.g., acetaminophen), but act on the same 
physiological pathways to reduce the neuro-chemical sensation of pain.   
Narcotic analgesics are used to treat moderate to severe pain, in many instances require a 
prescription from a prescriber that is licensed by the Drug Enforcement Agency (DEA). 
Perhaps the most widely used class of pain reliever in the United States is opioids, which 
can be subdivided into three types. First, naturally occurring (e.g., morphine or codeine) 
opioids are derived from the opium poppy plant. These drugs are typically altered into pro-
drugs during the pharmaceutical manufacturing process, meaning that they are chemically 
converted to opioids as they are metabolized into the body. This manufacturing strategy is 
preferable to leaving the chemical structure unaltered (i.e., free base) because it increases the 
bioavailability of the drugs during metabolization and therefore maximizes their efficacy. 
Naturally occurring opioids are also used as chemical building blocks for semi-synthetic 
opiates (e.g., hydrocodone, oxycodone). Both naturally occurring and semi-synthetic opioids 
attach to specific opioid receptors in the brain (e.g., Mu, Kappa, Delta, and Epsilon). Heroin 
is a semi-synthetic opioid that is similar in chemical structure to morphine and was 
primarily developed as a legitimate treatment for pain in the 1800s. However, it was 
discovered to have high affinity to abuse because it quickly activates the brain’s opioid 
neuro-receptors, thus producing a quick euphoric flush that is highly desirable by 
recreational abusers. Fully synthetic opioids (e.g., methadone, tramadol, 
dextropropoxyphene) are fully manufactured drugs and are not chemically related to 
opiates in structure, other than they selectively bind to the same neural receptors in the 
brain. There is controversy regarding the degree to which fully synthetic opioids have the 
same abuse liability as naturally occurring or semi-synthetic opioids (Aldworth, et al., 2010; 
Dasgupta, et al., 2011; Wu, Woody, Yang, Mannelli, et al., 2011). Overall, these drugs are 
known as exogenous opioids in that they are external stimuli, whereas endogenous opioids 
are produced internally (e.g., endorphins) in response to high levels of physical or emotional 
activity, and are secreted from the pituitary glands and attach to the opioid-like receptors in 
the brain.  
Epidemiology of Nonmedical and Disordered Use: The United States has one of the highest levels 
per capital consumption of prescription opioids (United Nations, 2004). While the use of 
narcotic opioids is recognized as an important weapon in the physician’s arsenal to combat 
mild to severe pain, studies have correlated high levels of exposure to nonmedical use and 
problematic levels to dependence (Dasgupta et al, 2006). Prescription pain relievers are the 
have the highest prevalence of nonmedical use, especially among youth aged 12-17 (Figure 
6). Between 2005 to 2009, approximately 6.5% of youth (pop est. 6,000 per 100,000) used a 
prescription pain reliever non-medically in the prior year. About 1/6 of those who abused 
also used at levels consistent with DSM-IV abuse and/or dependence. Among adults aged 
18 or older, the rates of nonmedical use were lower, approximately 4.5% (pop est. 4,500 per 
100,000). The rates of disordered use were similar to youth, with about 16 percent reporting 
symptoms of abuse and/or dependence.  
www.intechopen.com
 
Psychiatric Disorders – Trends and Developments 
 
380 
 
Fig. 6. Past Year Pain Reliever Use and Meeting Criteria for Dependence or Abuse of Pain 
Relievers, by Age and Year: 2005-2009 NSDUHs (Per 100,000) 
Treatment: Treatment for opioid pain medications tend toward the pharmacological 
spectrum, although some behavioral therapies do exist. The most common pharmacological 
treatment therapies for opioid pain medications include methadone, Buprenorphine, and 
Naltrexone or buprenorhpine/suboxone. Of the three, methadone is the oldest and most 
frequently used pharmacology (Amato et al., 2005), although limited evidence has shown 
that Buprenorphine may be slightly advantageous to methadone in terms of lessening 
withdrawal symptoms faster and overall completion of treatment (Gowing, Ali, & White, 
2004). In contrast, a systematic review of Naltrexone indicates that the treatment may not be 
very effective on treatment retention or abuse relapse rates (Minozzi et al., 2006). Although 
pharmacotherapies are popular with clinicians, trials on behavioral therapies have shown to 
be effective in the treatment of opioid pain medication abuse. These therapies have been 
found to increase treatment adherence as well as increase social support variables known to 
increase positive outcomes (Amato et al., 2008). Specific behavioral therapies like 
motivational interventions among prescription drug abusers have been shown to reduce use 
by 25% in over half of users (Zahradnik et al., 2009). 
5. Sedatives/tranquilizers 
This class of therapeutic medications is primary used to treat used to treat anxiety and 
sleep disorders. They are also a major source of drug overdoses and adverse drug 
reactions (DAWN, 2008). The effects of most sedative medications are mediated through 
the GABA-chloride receptor complex, and there have been specific neural-receptors that 
have a high affinity to benzodiazepines. These effects are potentiated with co-ingestion 
with other depressants, such as alcohol. At extremely high levels of use, 
sedatives/hypnotics produce a loss of coordination, euphoria, dyskinesia, and even 
hallucinations. There are primarily two classes of medications. Barbiturates are among the 
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oldest sedative/hypnotics and are sub-classified into their mechanism of duration 
(ultrashort acting, short acting, and long acting pharmacokinetics). The second major class 
is benzodiazepines. Unlike barbiturates, benzodiazepines are not useful for producing 
deep sedation and therefore are considered less powerful and of lower addictive 
potential. Because sedative/hypnotic drugs reduce neural excitability in the brain, neural 
adaption may occur after a period of weeks or months of prolonged use. Therefore, 
tapering rather than immediate withdrawal is recommended for patients who may 
develop physical tolerance after long-term exposure.  
Epidemiology of Nonmedical and Disordered Use: The rate of nonmedical use and disordered 
use is far lower for sedative/hypnotics than prescription pain relievers. As shown in 
Figure 7, approximately 2% of youth and adults reported nonmedical use in the prior 
year. Use also appeared stable between 2005 to 2009. Among those reporting use in the 
past year, approximately 16% of youth and adults met the criteria for abuse and/or 
dependence.  
 
 
Fig. 7. Past Year Sedative and Tranquilizer Use and Meeting Criteria for Dependence or 
Abuse of Sedatives and Tranquilizers, by Age and Year: 2005-2009 NSDUHs (Per 100,000|) 
Treatment: Other than tapering, many types of treatment seem to be effective in treating 
benzodiazepine abuse. Minimal intervention, such as receiving physician advice or a form 
letter from a physician as well as treatment programs led by physicians or counselors are 
two effective treatments (Voshaar, Couvee, van Balkom, Mulder, & Zitman, 2006). Tailored 
behavioral interventions have also been found to be particularly effective in benzodiazepine 
abusers (Ten Wolde et al., 2008; Tyrer et al., 1996). Behavioral therapy programs augmented 
with pharmacotherapies, such as imipramine also help to reduce use among abusers. Other 
pharmacotherapies such as Carbamazepine have also significantly improved drug 
abstinence among benzodiazepine abusers (Voshaar, Couvee, et al., 2006; Voshaar et al., 
2006; Voshaar et al., 2003). Behavioral interventions, such as cognitive behavioral therapy 
has also shown promise in reducing dependence (Denis, Fatseas, Lavie, & Auriacombe, 
2006).  
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6. Psychostimulants 
These drugs are typically used to treat attentional disorders (e.g., attention deficit disorder) 
and sleep disorders (e.g., narcolepsy). They are also compounds used in cold-medications 
because they are used to expand the nasal and esophageal airways and assist breathing (e.g., 
Ephedra). Ironically, low dosages of amphetamines actually produce a calming effect in 
those with attentional disorders. Drugs in this class are structurally related to a wide range 
of drugs that increase activation of the central nervous system. These include legitimate 
drugs such as caffeine and nicotine as illicit drugs such as crack cocaine. Prescription 
stimulants are typically referred to as amphetamines, and available in two chemical forms: I-
amphetamine (e.g., Benzedrine) and d-amphetamine (aka dextroamphetamine). 
Amphetamines have a high resemblance to the dopamine (DA) transmitter in their chemical 
structure, therefore have a high affinity to DA receptors in binding. Methamphetamine is 
perhaps the most potent form of amphetamine in its effects on the central nervous system. 
Illicit forms of methamphetamine (e.g., crystallize methamphetamine or crystal meth) are 
manufactured using processes to increase the speed of uptake in the brain because 
amphetamine is first metabolized in the liver and has a slow uptake and a long half life 
(about 7-30 hours depending upon the formulation).  
Epidemiology of Nonmedical and Disordered Use 
The recent rise of diagnoses for attentional disorders in the United States (Birnbaum, 2004) 
has placed an increased volume of amphetamine stimulants used to treat ADHD/ADD 
within the public domain. An estimated 4% of youth aged 17 or younger have been 
projected to meet the diagnostic criteria for AHDH/ADD. Of importance is that much of the 
data indicate that youth and adults who use ADHD/ADD stimulants non-medically do so 
for its purported therapeutic value rather than euphoria or to “get high.”  (McCabe, et al., 
2007; Novak et al., 2009). Epidemiological surveillance data from NSDUH (Figure 8) show 
 
 
Fig. 8. Past Year Stimulant Use and Meeting Criteria for Dependence or Abuse of 
Stimulants, by Age and Year: 2005-2009 NSDUHs (Per 100,000) 
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that less than 2% of youth and 1% of adults reported nonmedical use, and of these, about 7% 
report levels consistent with abuse and/or dependence. Therefore, there may be a 
significant amount of nonmedical use of prescription psychostimulants, the level of problem 
use is far lower than prescription pain relievers and sedatives/hypnotics.  
Treatment  
Treatments for prescription stimulants and tranquilizers/sedatives are primarily limited to 
behavioral therapies (Rawson et al., 1995), though novel drug targets are being developed 
for cocaine and amphetamine use. Interventions such as cognitive behavioral therapy (CBT) 
and contingency management which have proven moderately effective for cocaine and 
methamphetamine use disorders in achieving drug abstinence can be applied to persons 
abusing or dependent upon prescription stimulants. Tapering can be used initially to begin 
treatment which will ease the symptoms of withdrawal, following by CBT and contingency 
management. An extensive review of the literature indicated that the behavioral therapies 
being applied to illicit stimulant abuse are currently the best options for treatment of 
prescription stimulant abuse (Vocci & Montoya, 2009). Currently, there is no Food and Drug 
Administration approved medication for the treatment of prescription stimulants. 
7. Summary and future directions 
Nonmedical  prescription drug use had received a significant amount of policy and media 
attention in the past several years, with some using the term “epidemic” to describe the levels 
of use in the United States (Maxwell, 2011). In response, the Office of National Drug Control 
Policy (ONDCP), which is the policy arm of the President focused on substance abuse, issued a 
position statement in early 2011 (ONDCP, 2011). This policy release outlines the federal 
strategy for reducing nonmedical prescription drug abuse, and dictates various activities and a 
division of labor among federal agencies. The plan begins with patient and provider education 
programs across all federal health agencies. The content of which should focus on educating 
providers and patients on the safe and appropriate use of prescription medications, as well as 
the side effect profiles and the likelihood of abuse and diversion for nonmedical  purposes. A 
more detailed understanding of the sequence of substance use initiation would help identify 
optimal points for prevention and treatment. For example, it is unknown how many persons 
develop a prescription drug disorder after long-term exposure to prescription medications 
used in the treatment of a legitimate medical condition. This pathway may be different in 
terms of etiology and treatment needs from a “garbage head” or poly-drug user who uses 
multiple illicit substances. For this latter type of user, prescription drugs are either substituted 
when illicit drugs are unavailable, used to self-treat withdrawal symptoms, or used 
concurrently to increase the feelings of euphoria. Research has shown differences in 
motivations to use based on therapeutic and euphoric reasons (McCabe, Cranford, Boyd, & 
Teter, 2007; McCabe, Teter, & Boyd, 2006; Novak, Kroutil, Williams, & Van Brunt, 2007; 
Novak, Reardon, & Buka, 2002), but additional knowledge is needed to articulate the 
pathways leading from initiation to regular use and dependence.  
Tracking and enforcement are also primary goals outlined in the ONDCP Prescription Drug 
Control Strategy. While a large majority of the medications used for nonmedical purposes 
are obtained through friends and family, the highest volume consumers of prescription 
medications, who also meet the criteria for disordered use, obtain their medications through 
illicit channels such as doctor shopping, the internet, or theft (SAMHSA, 2009). There are a 
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number of initiatives to reduce the availability of prescription medications for diversion, 
such as “Medication Take Back Days” sponsored by local law enforcement in various states. 
In addition, drugs with even modest abuse liability, such as Tramadol—a non-opioid 
prescription pain reliever, are being rescheduled by several States so that prescribing and 
refilling practices by doctors and patients is more restrictive.  
In response to the public health threat that prescription drug abuse poses, federal and state 
initiatives in the United States have earmarked more than $500 million toward reducing the 
supply of NMPD through prescription monitoring programs, regulations for prescribing 
and dosing, and physician education programs (Fischer, Bibby, & Bouchard, 2010; Fishman, 
2011; Manchikanti, 2007). These programs are implemented in more than 40 states, with 
some form of legislation pending in the rest. Several screening instruments have also been 
developed to help clinicians identify potential abuse liability for their patient. 
Unfortunately, these programs and assessments have been developed and implemented in 
the absence of a strong scientific understanding of characteristics of prescription drug abuse. 
Medical professionals need guidance about types of NMPD to identify those with the 
greatest potential for abuse of a particular medication. It is also unknown whether 
individuals are aware of these monitoring systems and programs and if they have 
significantly affected drug procuring behaviors. 
This chapter began with an important statement about the complexities of the national drug 
problem involving prescription medications in the United States. This chapter presented 
descriptive epidemiological data on prescription drug disorders and their treatment. Unlike 
other drugs of abuse, the body of knowledge around prescription drug abuse is in its 
relative infancy. Many unresolved questions remain regarding the degree to which the risk 
factors for alcohol and tobacco and marijuana in adolescence are similar to prescription drug 
abuse. Resolution of this question would help frame primary prevention efforts toward 
either universal or specialized prevention programming in schools and in the community. 
Moreover, there are also many unknown questions about how the bio-pharmacological 
properties of prescription medications contribute toward abuse liability. Prescription drug 
manufacturers are developing abuse deterrent formulations (ADFs) of commonly abuse 
drugs. For example, several drugs in the FDA pipeline (Phase I to III) employ sequestered 
naltrexone, an opioid antagonist, to limit the nonmedical use of opioid-based pain 
medications. When the pill is crushed or tampered, the naltrexone becomes activated and 
counteracts the effects of the opioid concentrated in the medication. However, these 
methods are only effective against abuse by tampering (e.g., crushing, snorting, injecting), so 
additional methods are needed to curb routes of abuse that include oral ingestion as well. 
The health care delivery system for behavioral health is also under going tremendous 
transformation, which has wide-ranging implications for the prevention and treatment of 
prescription drug abuse. While the final proposed structure is likely to stay under 
significant and prolonged debate, experts agree that behavioral health, which is largely 
responsible for the delivery of substance abuse treatment services, will have greater 
integration into the primary and specialized health care systems. Taken together, it appears 
that a multi-pronged approach that involves effects at multiple systematic levels will be 
needed to reduce the epidemic of prescription drug abuse over the next several years.  
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Due to their prevalence, pervasiveness and burden inflicted on men and women of today, psychiatric disorders
are considered as one of the most important, sever and painful illnesses. This impairment of cognitive,
emotional, or behavioural functioning is in some cases tragic. Aside from knowing the physical organic factors,
such as infections, endocrinal illnesses or head injuries, the aetiology of psychiatric disorders has remained a
mystery. However, recent advances in psychiatry and neuroscience have been successful in discovering
subsequent pathophysiology and reaching associated bio-psycho-social factors. This book consists of recent
trends and developments in psychiatry from all over the world, presented in the form of multifarious and
comprehensive articles. The first two sections of the book are reserved for articles on schizophrenia and
depression, two major illnesses present in this field. The third section of the book is reserved for addiction
psychiatry, related not only to socio-cultural but also biological alterations. The last section of the book, titled
Biological Neuropsychiatry, consists of three topics - updated molecular biology, fundamental neuroscience
and clinical neuropsychiatric conditions. Doubtlessly, this book will be fruitful for future developments and
collaboration in world psychiatry.
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